HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

At Colgate Helm, Wallace Expected To Continue Cook's Strategies

Executive Summary

Noel Wallace, also named to board, says Colgate will continue to prioritize brand building, innovation in current product segments, expanding in channels and markets, maximizing e-commerce growth and investing to drive penetration in growing populations. He joined the oral, personal and home care product and pet nutrition company in 1987 and has served in senior management roles around the world.

You may also be interested in...



Colgate Shifts Innovation Focus From Growing Sales In Core Segments To Expanding Categories

Colgate shifts innovation focus to product launches that expand categories and grow sales for the long term. “We have to expand the pie in the categories that we compete … we’re not going to do that with simply core adjacencies,” says CEO Noel Wallace.

Coty’s Revolving Door Of CEOs; Revlon Chopping Heads; People News In Brief

Coty’s incoming CEO has more direct beauty experience than its past four going back to 2013. More people news.

Colgate’s Prestige Skin-Care Acquisitions Inspire Interest In Similar Deals

Colgate-Palmolive plans to “dial up investments” in prestige skin-care brands EltaMD and PCA Skin, which helped drive North American sales up 3% in the first quarter, says CEO Noel Wallace during his first quarterly presentation as CEO.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel